AP - Peregrine Pharmaceuticals Inc. said Thursday it cut its 2010 fiscal second-quarter loss nearly in half as revenue from manufacturing services and government payments for the antivirus drug candidate bavituximab increased sharply.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.